Hoche C, Dadak C, Kefalides A, Sinzinger H
Wien Klin Wochenschr. 1982 Oct 29;94(20):547-9.
Prostacyclin is the most potent endogenous inhibitor of platelet aggregation known so far, produced by endothelial and smooth muscle cells. This substance is assumed to play a key role in maintaining a sufficient blood flow in maternal and fetal circulation. There is now some evidence that there is a non-cellular component in human blood, which is able to influence the prostacyclin formation to a certain degree, the so-called "prostacyclin synthesis stimulating plasma factor". A change in the plasma factor activity in patients with a disturbance of PGI2 metabolism has been observed. We examined the activity of this plasma factor during pregnancy and one year after delivery. During the first and second trimenon increased values were observed, whereas at the end of pregnancy the values were significantly decreased. The values for plasma factor activity one year after delivery were comparable to those of the control group. In patients with diabetes mellitus decreased activity of the plasma factor was observed, but its course was similar to that seen in normal pregnancy.
前列环素是目前已知的最有效的内源性血小板聚集抑制剂,由内皮细胞和平滑肌细胞产生。这种物质被认为在维持母婴循环中充足的血流方面起关键作用。现在有一些证据表明,人血液中存在一种非细胞成分,它能够在一定程度上影响前列环素的形成,即所谓的“前列环素合成刺激血浆因子”。已经观察到前列环素(PGI2)代谢紊乱患者血浆因子活性的变化。我们研究了孕期及产后一年该血浆因子的活性。在妊娠的前三个月和第二个三个月观察到活性值升高,而在妊娠末期值显著降低。产后一年血浆因子活性值与对照组相当。在糖尿病患者中观察到血浆因子活性降低,但其变化过程与正常妊娠相似。